5 Best Healthcare Stocks to Buy for the Long Term

3. Jazz Pharmaceuticals (NASDAQ:JAZZ)

Number of Hedge Fund Holders: 64

Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the best healthcare stocks to buy for the long term. Jazz Pharmaceuticals (NASDAQ:JAZZ) received several rating updates following the release of financial results for fiscal Q1 2026 on May 5, where it reported strong commercial execution across franchises with total revenues of $1.1 billion, up 19% year-over-year.

Raymond James lifted the price target on Jazz Pharmaceuticals (NASDAQ:JAZZ) to $239 from $227 on May 7, reaffirming an Outperform rating on the shares. The firm told investors in a research note that the company is up 25% year-to-date, with investors beginning to understand that Jazz Pharmaceuticals (NASDAQ:JAZZ) is in the early innings of a transformation from a spec pharma story to an innovation-led biotech story. This holds especially true following Zani’s highly competitive readout in 1L GEA and priority review, according to the firm.

Jazz Pharmaceuticals (NASDAQ:JAZZ) also received a rating update from TD Cowen the same day, with the firm lifting the price target on the stock to $275 from $220 and maintaining a Buy rating on the shares.

Jazz Pharmaceuticals (NASDAQ:JAZZ) develops medicines for serious diseases. Its primary marketed products include Xywav, Xyrem oral solution, Epidiolex oral solution, Rylaze, Zepzelca, Defitelio, and Vyxeos liposome for injection. These medicines treat excess daytime sleepiness (EDS) in narcolepsy patients seven years of age or older, tepatic veno-occlusive disease (VOD), and other ailments.